Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Cash Flow (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Net Cash Flow for 15 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 218.58% year-over-year to $3.2 million, compared with a TTM value of -$18.4 million through Sep 2025, down 165.8%, and an annual FY2024 reading of $13.4 million, up 227.23% over the prior year.
  • Net Cash Flow was $3.2 million for Q3 2025 at Fennec Pharmaceuticals, up from -$4.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $37.9 million in Q1 2024 and bottomed at -$13.7 million in Q4 2024.
  • Average Net Cash Flow over 5 years is -$132352.9, with a median of -$3.4 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 804.22% in 2024, while the deepest fall reached 1673.1% in 2024.
  • Year by year, Net Cash Flow stood at $542000.0 in 2021, then crashed by 1202.95% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870000.0 in 2023, then tumbled by 1673.1% to -$13.7 million in 2024, then surged by 123.69% to $3.2 million in 2025.
  • Business Quant data shows Net Cash Flow for FENC at $3.2 million in Q3 2025, -$4.0 million in Q2 2025, and -$4.0 million in Q1 2025.